Compare USCB & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USCB | RCEL |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.1M | 403.3M |
| IPO Year | 2021 | 2018 |
| Metric | USCB | RCEL |
|---|---|---|
| Price | $19.87 | $15.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $23.25 | $13.57 |
| AVG Volume (30 Days) | 71.1K | ★ 393.1K |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | 7.26 | ★ 27.20 |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | ★ $71,610,000.00 |
| Revenue This Year | $20.63 | $23.78 |
| Revenue Next Year | $7.64 | $26.87 |
| P/E Ratio | $19.85 | ★ N/A |
| Revenue Growth | N/A | ★ 11.45 |
| 52 Week Low | $17.00 | $3.22 |
| 52 Week High | $23.89 | $16.90 |
| Indicator | USCB | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 28.77 | 65.27 |
| Support Level | $19.08 | $3.86 |
| Resistance Level | $20.19 | N/A |
| Average True Range (ATR) | 0.61 | 0.86 |
| MACD | -0.24 | 0.12 |
| Stochastic Oscillator | 18.83 | 68.33 |
USCB Financial Holdings Inc is a bank holding company. Through its banking subsidiary, it offers relationship-based banking products, services, and solutions to a diverse set of clients in the local markets it operates in and international clients with U.S. banking needs. The Group's products and services offerings mainly include traditional deposit products, including commercial and consumer checking accounts, money market deposit accounts, savings accounts, etc.; e-banking services; title insurance policies for real estate transactions; and a variety of lending products such as small business loans, commercial real estate loans, business credit cards, etc.; and others. Geographically, its primary banking market is South Florida.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.